## SEC Form 4

(City)

## FORM 4

(State)

(Zip)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

		Washington, D.C. 20040	OMB A	OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMEN	IT OF CHANGES IN BENEFICIAL OWN	Estimated aver	OMB Number: 3235-0287 Estimated average burden			
obligations may continue. See Instruction 1(b).	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	1	hours per resp	oonse: 0.5		
1. Name and Address of Reporting Personal Nandabalan Krishnan	on*	2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI]	(Check all applic X Directo	r	10% Owner		
(Last) (First) C/O BIOXCEL THERAPEUTICS	(Middle) S, INC.,	3. Date of Earliest Transaction (Month/Day/Year) 07/24/2020	below)	(give title	Other (specify below)		
555 LONG WHARF DRIVE		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or J Line)	oint/Group Filing	(Check Applicable		
(Street) NEW HAVEN CT 06511				led by One Report led by More than (	0		

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock	04/01/2019		G		1,000	D	\$ <mark>0</mark>	0	D	
Common Stock	04/01/2019		G		1,000	Α	\$0	1,000	Ι	By trust <sup>(1)</sup>
Common Stock	07/24/2020		J <sup>(2)(3)</sup>		160,000	D	\$60.76	9,020,000 <sup>(2)(3)</sup>	I	See footnotes <sup>(2)(3)</sup>
Common Stock	07/24/2020		J <sup>(4)</sup>		80,000	Α	\$60.76	80,000	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Shares held by The Sunanda Family Trust.

2. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder.

3. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

4. See footnote (2). These securities were acquired as the result of the distribution of the Issuer's common stock by Parent to the Reporting Person in return for the cancellation of a proportional number of shares owned in Parent owned by the Reporting Person.

/s/ Richard Steinhart, as

02/16/2021 Attorney in Fact for Krishnan Nandabalan

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.